Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 501–600 of 1,004
Targeting Notch to overcome radiation resistance
Yahyanejad, S., Theys, J., & Vooijs, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6714 · Cited by 79
Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities
Wong, E. T., & Brem, S. S. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0039 · Cited by 74
Clavreul, A., Roger, E., Masouleh, M. P., Lemaire, L. P., Tétaud, C., & Meneï, P. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1507061 · Cited by 71
Liu, H., Jiang, W., Wang, Q., Hang, L., Wang, Y., & Wang, Y. (2019) · Biomaterials Science · doi:10.1039/c9bm00634f · Cited by 73
Matsumoto, G., Kushibiki, T., Kinoshita, Y., Lee, U., Omi, Y., Kubota, E., & Tabata, Y. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00174.x · Cited by 77
Bevacizumab in the treatment of colorectal cancer
Mulcahy, M. F., & Benson, A. B. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.7.997 · Cited by 71
Velde, E. A. T., Vogten, J. M., Gebbink, M. F. B. G., van Gorp, J. M., Voest, E. E., & Rinkes, I. H. M. B. (2002) · British journal of surgery · doi:10.1046/j.1365-2168.2002.02183.x · Cited by 71
Lee, S. C., Shimasaki, N., Lim, J. S. J., Wong, A. L., Yadav, K., Yong, W. P., Tan, L. K., Koh, L. P., Poon, M. L. M., Tan, S. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0768 · Cited by 74
Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction
Lee, Y.-J., Lee, H.-J., Choi, S.-H., Jin, Y. B., Kang, J. H., Kang, J.-H., Yoon, S. S., & Lee, Y. (2012) · Angiogenesis · doi:10.1007/s10456-012-9255-3 · Cited by 70
Kim, W., & Lee, H. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07177.x · Cited by 72
Cancer Stem Cells and Tumor Response to Therapy: Current Problems and Future Prospects
Milas, L., & Hittelman, W. N. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.11.004 · Cited by 77
Kiessling, F. M., Farhan, N., Lichy, M. P., Vosseler, S., Heilmann, M., Krix, M., Böhlen, P., Miller, D. W., Mueller, M. M., Semmler, W., et al. (2004) · Neoplasia · doi:10.1593/neo.03394 · Cited by 70
Ulahannan, S. V., & Brahmer, J. R. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.554476 · Cited by 72
Weathers, S.-P. S., Han, X., Liu, D. D., Conrad, C. A., Gilbert, M. R., Loghin, M. E., O'Brien, B. J., Peñas-Prado, M., Puduvalli, V. K., Tremont‐Lukats, I. W., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2195-9 · Cited by 72
Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials
Huang, A., Pressnall, M. M., Lu, R., Huayamares, S. G., Griffin, J. D., Groer, C. E., DeKosky, B. J., Forrest, M. L., & Berkland, C. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.029 · Cited by 70
Management of advanced hepatocellular carcinoma in the era of targeted therapy
Yau, T. C. C., Chan, P., Epstein, R. J., & Poon, R. T. P. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01916.x · Cited by 69
Angiogenesis and vascular targeting in Ewing sarcoma: A review of preclinical and clinical data
DuBois, S. G., Marina, N. M., & Bender, J. G. (2009) · Cancer · doi:10.1002/cncr.24844 · Cited by 69
Goss, G. D., Shepherd, F. A., Laurie, S. A., Gauthier, I. C., Leighl, N. B., Chen, E. X., Feld, R. D., Powers, J., & Seymour, L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.022 · Cited by 69
Zweifel, M., & Padhani, A. R. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1451-z · Cited by 69
Weidle, U. H., Niewöhner, J., & Tiefenthaler, G. (2015) · PubMed · Cited by 78
Ito, K., Hamamichi, S., Abe, T., Akagi, T., Shirota, H., Kawano, S., Asano, M., Asano, O., Yokoi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13392 · Cited by 72
Can tumor angiogenesis be inhibited without resistance?
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7311-3_7 · Cited by 73
Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?
Herbst, R. S., & Sandler, A. B. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-19 · Cited by 72
Strieth, S., Eichhorn, M., Werner, A., Sauer, B., Teifel, M., Michaelis, U., Berghaus, A., & Dellian, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4738 · Cited by 68
Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow
de Langen, A. J., van den Boogaart, V., Marcus, J. T., & Lubberink, M. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0235 · Cited by 78
Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors
Al-Abd, A. M., Aljehani, Z. K., Gazzaz, R. W., Fakhri, S. H., Jabbad, A. H., Alahdal, A. M., & Torchilin, V. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.055 · Cited by 69
Peng, F., Xu, Z., Wang, J., Chen, Y., Li, Q., Zuo, Y., Chen, J., Hu, X., Zhou, Q.-C., Wang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034646 · Cited by 72
Guibal, A., Taillade, L., Mulé, S., Compérat, É., Badachi, Y., Golmard, J. L., Guillou‐Buffello, D. L., Rixe, O., Bridal, S. L., & Lucidarme, O. (2010) · Radiology · doi:10.1148/radiol.09090728 · Cited by 67
Kan, Z., Kobayashi, S., Phongkitkarun, S., & Charnsangavej, C. (2005) · Radiology · doi:10.1148/radiol.2371040526 · Cited by 67
Hypoxia and Hypoxia Inducible Factors (HIF) as Important Regulators of Tumor Physiology
Acker, T., & Plate, K. H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_14 · Cited by 75
Bzyl, J., Palmowski, M., Rix, A., Arns, S., Hyvelin, J.-M., Pochon, S., Ehling, J., Schrading, S., Kiessling, F. M., & Lederle, W. (2012) · European Radiology · doi:10.1007/s00330-012-2594-z · Cited by 66
Hypoxia Imaging in Gliomas With 18F-Fluoromisonidazole PET: Toward Clinical Translation
Bell, C., Dowson, N., Fay, M., Thomas, P. A., Puttick, S. G., Gal, Y., & Rose, S. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.001 · Cited by 68
Ferretti, S., ALLEGRINI, P. R., O’Reilly, T., Schnell, C., Stumm, M., Wartmann, M., Wood, J. M., & McSheehy, P. M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1165 · Cited by 66
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700913.x · Cited by 71
Zhang, L., Takara, K., Yamakawa, D., Kidoya, H., & Takakura, N. (2015) · Cancer Science · doi:10.1111/cas.12836 · Cited by 68
McDonald, D. M., & Bałuk, P. (2005) · CHEST Journal · doi:10.1378/chest.128.6_suppl.602s-a · Cited by 65
Libertini, S., Iacuzzo, I., Perruolo, G., Scala, S., Ieranò, C., Franco, R., Halldén, G., & Portella, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0200 · Cited by 65
Metabolic Tumor Profiling with pH, Oxygen, and Glucose Chemosensors on a Quantum Dot Scaffold
Lemon, C. M., Curtin, P. N., Somers, R. C., Greytak, A. B., Lanning, R. M., Jain, R. K., Bawendi, M. G., & Nocera, D. G. (2013) · Inorganic Chemistry · doi:10.1021/ic401587r · Cited by 66
Self-citationLi, W., Quan, Y.-Y., Li, Y., Lu, L., & Cui, M. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174712 · Cited by 61
Ning, L., Shim, J., Tomov, M. L., Liu, R., Mehta, R., Mingee, A., Hwang, B., Jin, L., Mantalaris, A., Xu, C., et al. (2022) · Advanced Science · doi:10.1002/advs.202200244 · Cited by 68
Advances in nanoparticle-based radiotherapy for cancer treatment
He, M., Chen, S., Yu, H., Fan, X., Wu, H., Wang, Y., Wang, H., & Yin, X. (2024) · iScience · doi:10.1016/j.isci.2024.111602 · Cited by 71
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours
Thompson, G., Mills, S. J., Coope, D. J., O’connor, J. P. B., & Jackson, A. (2011) · The British Journal of Radiology · doi:10.1259/bjr/66316279 · Cited by 61
Liu, G., Jeraj, R., Vanderhoek, M., Perlman, S. B., Kolesar, J., Harrison, M. R., Simončič, U., Eickhoff, J. C., Carmichael, L. L., Chao, B. H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1677 · Cited by 66
Li, Q., Yano, S., Ogino, H., Wang, W., Uehara, H., Nishioka, Y., & Sone, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0501 · Cited by 64
Targeting the tumor vascular compartment to improve conventional cancer therapy
Féron, O. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.08.008 · Cited by 72
Role of hypoxia in tumor angiogenesis?molecular and cellular angiogenic crosstalk
Acker, T., & Plate, K. H. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0763-8 · Cited by 71
Radiation Combined With Antiangiogenic and Antivascular Agents
OʼReilly, M. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.006 · Cited by 66
Xu, X., Mu, L., Li, L., Liang, J., Zhang, S., Jia, L., Yang, X., Dai, Y., Zhang, J., Wang, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abi8683 · Cited by 66
Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas
de Groot, J., & Yung, W. K. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e3181867bd6 · Cited by 65
Qian, C., Tan, M., Yang, J., & Cao, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-015-0070-2 · Cited by 63
Ledzewicz, U., Maurer, H., & Schättler, H. (2011) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2011.8.307 · Cited by 63
Li, L., Liang, X., Xu, Y., Yang, Y., Li, X., & Dai, Z. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00407 · Cited by 64
Newsome, B. W., & Ernstoff, M. S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03187.x · Cited by 77
Olson, P., & Hanahan, D. (2009) · Science · doi:10.1126/science.1175940 · Cited by 62
Tumor microenvironment and nanotherapeutics: intruding the tumor fort
Kiran, A. V. V. V. R., Kumari, G. K., Krishnamurthy, P. T., & Khaydarov, R. R. (2021) · Biomaterials Science · doi:10.1039/d1bm01127h · Cited by 64
Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy
Mpekris, F., Voutouri, C., Panagi, M., Baish, J. W., Jain, R. K., & Stylianopoulos, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.008 · Cited by 62
Self-citationSunar, U., Makonnen, S., Zhou, C., Durduran, T., Yu, G., Wang, H.-W., Lee, W. M., & Yodh, A. G. (2007) · Optics Express · doi:10.1364/oe.15.015507 · Cited by 65
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Navid, F., Santana, V. M., Neel, M. D., McCarville, M. B., Shulkin, B. L., Wu, J., Billups, C. A., Mao, S., Daryani, V. M., Stewart, C. F., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30841 · Cited by 62
Du, S. M., Xiong, H., Xu, C., Lu, Y., & Yao, J. (2019) · Biomaterials Science · doi:10.1039/c8bm01350k · Cited by 62
Zhang, X., Zeng, L., Li, Y., Xu, Q., Yang, H., Lizaso, A., Mao, X., Jin, R., Zeng, Y., Li, Q., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02869-9 · Cited by 63
Tumor-associated macrophages in thoracic malignancies
Lievense, L. A., Bezemer, K., Aerts, J. G. J. V., & Hegmans, J. P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.017 · Cited by 65
Hansen, T. F., Christensen, R. D., Andersen, R. F., Spindler, K. G., Johnsson, A., & Jakobsen, A. K. M. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1382-6 · Cited by 61
Deep, G., & Agarwal, R. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990041 · Cited by 66
Pysz, M. A., Foygel, K., Panje, C. M., Needles, A., Tian, L., & Willmann, J. K. (2010) · Investigative Radiology · doi:10.1097/rli.0b013e3181f9202d · Cited by 61
Marty, M. E., & Pivot, X. B. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.005 · Cited by 69
Wang, J., Ma, Y., Jiang, H., Zhu, H., Liu, L., Sun, B., Pan, S., Krissansen, G. W., & Sun, X. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.043 · Cited by 61
Vessel pruning or healing: endothelial metabolism as a novel target?
Cantelmo, A. R., Pircher, A., Kalucka, J. M., & Carmeliet, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1282465 · Cited by 64
Chandra, A., Jahangiri, A., Chen, W., Nguyen, A. T., Yagnik, G., Pereira, M. P., Jain, S., Garcia, J. H., Shah, S. S., Wadhwa, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1305 · Cited by 64
Wang, K., Chen, Q., Liu, N., Zhang, J., & Pan, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.024 · Cited by 63
Fujita, K., Sano, D., Kimura, M., Yamashita, Y., Kawakami, M., Ishiguro, Y., Nishimura, G., Matsuda, H., & Tsukuda, M. (2007) · Oncology Reports · doi:10.3892/or.18.1.47 · Cited by 61
Esophagogastric cancer: Targeted agents
Ku, G. Y., & Ilson, D. H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.009 · Cited by 63
Liang, C., Zhang, X., Yang, M., Wang, W., Chen, P., & Dong, X. (2020) · ACS Materials Letters · doi:10.1021/acsmaterialslett.0c00259 · Cited by 62
Qian, C., Yang, C., Tang, Y. R., Zheng, W., Zhou, Y., Zhang, S., Song, M., Cheng, P., Wei, Z., Zhong, C., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106333 · Cited by 60
The application of magnetic nanoparticles for the treatment of brain tumors
Mahmoudi, K., & Hadjipanayis, C. G. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00109 · Cited by 65
Are Cancer Stem Cells Radioresistant?
Hittelman, W. N., Liao, Y., Wang, L., & Milas, L. (2010) · Future Oncology · doi:10.2217/fon.10.121 · Cited by 65
Diagnostic Accuracy of Contrast-Enhanced Ultrasound Enhancement Patterns for Thyroid Nodules
Zhang, Y., Luo, Y.-K., Zhang, M., Li, J., Li, J., & Tang, J. (2016) · Medical Science Monitor · doi:10.12659/msm.899834 · Cited by 60
Amino acid PET and MR perfusion imaging in brain tumours
Filß, C., Cicone, F., Shah, N. J., Galldiks, N., & Langen, K. (2017) · Clinical and Translational Imaging · doi:10.1007/s40336-017-0225-z · Cited by 60
Precision Therapy of Head and Neck Squamous Cell Carcinoma
Polverini, P. J., D’Silva, N. J., & Lei, Y. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518769645 · Cited by 62
Tanabe, K., Zhang, Z., Itô, T., Hatta, H., & Nishimoto, S. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b711244k · Cited by 63
Ansiaux, R., Baudelet, C., Jordan, B. F., Crokart, N., Martinive, P., DeWever, J., Grégoire, V., Feron, O., & Gallez, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1854 · Cited by 60
Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles
Sonveaux, P., Dessy, C., Martinive, P., Havaux, X., Jordan, B. F., Gallez, B., Grégoire, V., Balligand, J.-L., & Feron, O. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1291 · Cited by 59
Goshen, E., Davidson, T., Zwas, S. T., & Aderka, D. (2006) · Technology in Cancer Research & Treatment · doi:10.1177/153303460600500105 · Cited by 60
Schmidt, N. O., Ziu, M., Carrabba, G. G., Giussani, C. G., Bello, L., Sun, Y., Schmidt, K. F., Albert, M., Black, P. M., & Carroll, R. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0052 · Cited by 60
Quantifying tissue microvasculature with speckle variance optical coherence tomography
Conroy, L., DaCosta, R. S., & Vitkin, I. A. (2012) · Optics Letters · doi:10.1364/ol.37.003180 · Cited by 62
Weiss, A., B, J. R. V. B., Bonvin, D., Jichlinski, P., Dyson, P. J., Griffioen, A. W., & Nowak-Sliwinska, P. M. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12199 · Cited by 59
Chang, Y., Yu, C., Chen, C., Hu, F., Hsu, H., Tseng, W. I., Shih, T. T., Yang, P., & Yang, J. C. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23660 · Cited by 59
Selvakumaran, M., Yao, K. S., Feldman, M. D., & O'Dwyer, P. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.029 · Cited by 60
Dosa, E., Guillaume, D. J., Haluska, M., Lacy, C. A., Hamilton, B. E., Njus, J. M., Rooney, W. D., Kraemer, D. F., Muldoon, L. L., & Neuwelt, E. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq172 · Cited by 55
Systemic Therapies in Hepatocellular Carcinoma
Wörns, M., Weinmann, A., Schuchmann, M., & Galle, P. R. (2009) · Digestive Diseases · doi:10.1159/000218351 · Cited by 65
Hijacking the vasculature in ccRCC—co-option, remodelling and angiogenesis
Qian, C.-N. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.26 · Cited by 62
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R. J. H., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 59
Self-citationGuérin, O., Formento, P., Nigro, C. L., Hofman, P. M., Fischel, J., Étienne-Grimaldi, M.-C., Merlano, M. C., Ferrero, J.-M., & Milano, G. A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0247-4 · Cited by 58
Cancer Detection and Treatment: The Role of Nanomedicines
LaRocque, J., Bharali, D. J., & Mousa, S. A. (2009) · Molecular Biotechnology · doi:10.1007/s12033-009-9161-0 · Cited by 58
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
Bordeau, B. M., & Balthasar, J. P. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0704 · Cited by 58
The use of the orthotopic model to validate antivascular therapies for cancer
Loi, M., Paolo, D. D., Becherini, P., Zorzoli, A., Perri, P., Carosio, R., Cilli, M., Ribatti, D., Brignole, C., Pagnan, G., et al. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103230ml · Cited by 59
Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?
Zhu, A. X. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0975-6 · Cited by 57
Targeted therapies of cancer: Angiogenesis inhibition seems not enough
Roodink, I., & Leenders, W. P. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.004 · Cited by 62
Liu, D., Wu, Q., Zhu, Y., Liu, Y., Xie, X., Li, S., Lin, H., Chen, W., & Zhu, F. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1609623 · Cited by 56
Regulation of tumor microenvironment for pancreatic cancer therapy
Huang, X., Ding, L., Liu, X., Tong, R., Ding, J., Qian, Z., Cai, L., Zhang, P., & Li, D. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120680 · Cited by 61
Falk, T., Gonzalez, R. T., & Sherman, S. J. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11082875 · Cited by 60
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.